Philip MD - Apellis Pharmaceuticals Chief Advisor

Apellis Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.1377) % which means that it has lost $0.1377 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0849) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2025. Return On Capital Employed is likely to drop to -0.25 in 2025. At this time, Apellis Pharmaceuticals' Non Current Assets Total are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 29.7 M in 2025, whereas Total Current Assets are likely to drop slightly above 445.4 M in 2025.

Similar Executives

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. Apellis Pharmaceuticals (APLS) is traded on NASDAQ Exchange in USA. It is located in 100 Fifth Avenue, Waltham, MA, United States, 02451 and employs 705 people. Apellis Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Apellis Pharmaceuticals Leadership Team

Apellis Stock Performance Indicators

Additional Tools for Apellis Stock Analysis